Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — April 2024

Biotek-snakken — April 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
112 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #43

    ... we remain
    optimistic and expect the first (organically) profitable quarter to be
    Q3 2024 – if the company continues to step up its commercial
    efforts. With the updated forecasts, we have reached a fair value
    of SEK 177 but have decided to maintain our target price of SEK
    161 due to low growth expected for Q1 2024."

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #44

      "Pareto upprepar köp för Calliditas inför rapporten - fortsatt optimistiska"

      (Finwire)

      1 Reply Last reply
      0
      • F Offline
        F Offline
        Fandel
        wrote on sidst redigeret af
        #45

        Godmorgen...

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #46

          Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis https://www.proinvestor.com/investornyt/1145923/alvotech-and-teva-fda-approves-selarsdi-injection-for-psoriasis-and-psoriatic-arthritis

          1 Reply Last reply
          0
          • L Offline
            L Offline
            LP90
            wrote on sidst redigeret af
            #47

            Godmorgen 🙂

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #48

              ULTIMOVACS: Biotekselskapet melder at de vil redusere antall ansatte med 40% slik at de skal ha likviditet til å nå ytterligere to datapunkter - pengene skal etter plan holde til Q4 2025.

              1 Reply Last reply
              0
              • F Offline
                F Offline
                Fandel
                wrote on sidst redigeret af
                #49

                Godmorgen...

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  LP90
                  wrote on sidst redigeret af
                  #50

                  Godmorgen 🙂

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #51

                    Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

                    Link Preview Image
                    Calliditas Therapeutics AB

                    Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                    favicon

                    Calliditas Therapeutics AB (www.calliditas.se)

                    1 Reply Last reply
                    0
                    • F Offline
                      F Offline
                      Fandel
                      wrote on sidst redigeret af
                      #52

                      Godmorgen...

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #53

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • F Offline
                          F Offline
                          Fandel
                          wrote on sidst redigeret af
                          #54

                          Godmorgen...

                          1 Reply Last reply
                          0
                          • F Offline
                            F Offline
                            Fandel
                            wrote on sidst redigeret af
                            #55

                            Godmorgen...

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #56

                              BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease https://www.proinvestor.com/investornyt/1148131/bioarctic-and-eisai-collaborate-on-evaluating-ban2802-for-alzheimers-disease

                              1 Reply Last reply
                              0
                              • H Offline
                                H Offline
                                Hansen
                                wrote on sidst redigeret af
                                #57

                                Xbane lidt nyt https://xbrane.com/mfn_news/xbrane-uppdaterar-kring-fdas-granskning-av-ranibizumab-biosimilarkandidat/

                                1 Reply Last reply
                                0
                                • H Offline
                                  H Offline
                                  Hansen
                                  wrote on sidst redigeret af
                                  #58

                                  Xbrane 🙂

                                  1 Reply Last reply
                                  0
                                  • F Offline
                                    F Offline
                                    Fandel
                                    wrote on sidst redigeret af
                                    #59

                                    Godmorgen...

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      LP90
                                      wrote on sidst redigeret af
                                      #60

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #61

                                        God morgen 🙂

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #62

                                          En fabriksorienteret Complete Response Letter (CRL) kan typisk resultere i en forlængelse på 1 til 6 måneder, men i visse tilfælde kan forlængelsen vare op til 12 måneder eller mere.

                                          "Receiving a complete response letter is not a rejection, but it introduces important business questions for product launch planning."

                                          https://avalere.com/insights/what-is-a-complete-response-letter

                                          (Avalere)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper